Lotus Pharmaceutical
Highly Engaged Employees
Manufacturing · Taiwan · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
17f no. 277 Song Ren Rd, Xin Yi District...Phone Number
+886 227005908Website
www.lotuspharm.comRevenue
$395.4 MillionIndustry
About Lotus Pharmaceutical
Lotus Pharmaceutical Org Chart
Is Lotus Pharmaceutical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Lotus Pharmaceutical has new funding data
Product Launch: Get notified when Lotus Pharmaceutical launches new products
Congratulate Masked Content for being promoted to Masked Content at Lotus Pharmaceutical
Check out if Lotus Pharmaceutical is spiking on competitors!
Click to see if Lotus Pharmaceutical had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Lotus Pharmaceutical has recently received funding, and reach out quickly before it becomes old news!
Lotus Pharmaceutical, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Lotus Pharmaceutical recently announced quarterly report
Recommended Actions
Find VP level buyers at Lotus Pharmaceutical
Find 3 more new buyers
Company Profile Activity
Activity Insights
Lotus Pharmaceutical is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lotus Pharmaceutical is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lotus Pharmaceutical.
Lotus Pharmaceutical Tech Stack
A closer look at the technologies used by Lotus Pharmaceutical
Most Recent Scoops
Lotus Pharmaceutical News & Media
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
Exclusive agreement includes up to $125 million in upfront and milestone payments to LENZ together with double-digit royalties on future net sales Exclusive agreement includes up to $125 million in upfront and milestone payments to LENZ together with double-digit royalties on future net salesNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Reports Comments by Strategic Partner Lotus Pharmaceutical Co. Ltd. (1975.TW) in Recent Financial Report
Companies continue to work collaboratively to advance NRX-101 in bipolar depression with suicidality Lotus notes that NRx has "achieved a significant milestone by completing enrollment for its phase 2b/3 trial of NRX-101 in suicidal treatment-resistant bipolar depression. The readout for...NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101
RADNOR, Pa. and MORRISTOWN, N.J. and TAIPEI, Taiwan, June 05, 2023 (GLOBE NEWSWIRE) -- Lotus Pharmaceuticals (1795:TT; “Lotus”), a multinational pharmaceutical company, Alvogen, a privately owned U.S. based pharmaceuticals company, and NRx Pharmaceuticals Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals or NRx”), a clinical stage biopharmaceutical company, today announced a global collaboration agreement covering the development and commercialization of NRX-101 for suicidal treatment-resistant bipolarUnicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
Develops Renazorb opportunity in new market for patients with hyperphosphatemia
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lotus Pharmaceutical
Lotus Pharmaceutical is a global pharmaceutical company focused on developing, manufacturing, and commercializing generic and specialty medicines. It operates research and manufacturing facilities across Asia and supplies treatments for areas such as oncology, cardiovascular disease, and central nervous system conditions, aiming to improve access t... Read More